Press Release
20 November 2026 08:30:00 CET

Oncopeptides announces the Nomination Committee

Stockholm – November 20, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the composition of the Nomination Committee has been established.

According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the Annual General Meeting 2027 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of the end of the third quarter 2026 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors.

The Nomination Committee in respect of the Annual General Meeting 2027 consists of the following persons, who together represent approximately 16 percent of the votes in the company based on shareholder information at the end of September 2026:

- Staffan Lindstrand, appointed by HealthCap VI L.P. and HealthCap VIII L.P.
- Ulf Nolén, representing his own shareholding
- Philip Lennhammer, appointed by Madeleine Lennhammer
- Per Wold-Olsen, Chairman of the Board

The Nomination Committee's proposals will be presented in the notice to the Annual General Meeting 2027 and on Oncopeptides' website, www.oncopeptides.com.

Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to info@oncopeptides.com (subject "Nomination Committee") or by letter to:

Oncopeptides AB (publ)
Attn: Oncopeptides Nomination Committee
Luntmakargatan 46
SE-111 37 Stockholm
Sweden

Proposals must reach the Nomination Committee no later than April 1, 2027, to be eligible for inclusion in the notice and agenda for the Annual General Meeting.

For more information, please contact:

David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)
E-mail: ir@oncopeptides.com
Cell phone: +46 76 229 38 68

About Oncopeptides

Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 70 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: www.oncopeptides.com

Attachments

Oncopeptides announces the Nomination Committee